Topic: non-small cell lung cancer
Roche has been chomping at the bit to challenge Merck in previously untreated lung cancer, but it’s going to have to wait a little longer.
Merck’s Keytruda is one step closer to extending its dominance in the all-important previously untreated lung cancer market.
Excluding ALK and EGFR, about two-thirds of new NSCLC patients are now starting their treatment with Keytruda, said an executive.
Eisai and Biogen's recent Alzheimer's data spark debate; Beijing works to contain a vaccine scandal; BMS and Tsinghua University pen drug discovery pact.
Roche's first-half sales climbed 7% to $28.3 billion, their fastest clip in about three years, thanks to stepped-up performance from its newer drugs.
Takeda's Alunbrig now sits in the back seat in ALK+ lung cancer, behind rivals from Pfizer, Novartis and Roche—but some new data could help change that.
Roche touted another win Thursday for Tecentriq. But the way some analysts see things, it may actually be a win for Merck's Keytruda
Tagrisso will enjoy quick uptake in a couple of new indications to win 95% of EGFR-mutated NSCLC patients by 2020, a bullish analyst figures.
BMS' Opdivo is finally under FDA consideration as a therapy for previously untreated lung cancer.
Opdivo goes directly to the lucrative lung cancer market with its first nod in China, where nearly 800,000 new patients are diagnosed each year.